Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

Thursday, June 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has announced the acquisition of worldwide exclusive rights to MIRA-55 and SKNY-1, enhancing its strategic flexibility for future licensing and partnership opportunities. This agreement solidifies MIRA's position in the development of therapeutics targeting neurologic, neuropsychiatric, inflammatory, and metabolic disorders. The move is expected to strengthen MIRA's core therapeutic pipeline significantly.
Price reaction · baseline $1.01 (2026-06-03 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+5%

Market Sentiment Analysis

POSITIVE FACTORS

  • MIRA Pharmaceuticals secures worldwide exclusive rights to key therapeutics.
  • The agreement enhances strategic flexibility for future partnerships.
  • Focus on proprietary therapeutics for various disorders indicates strong pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Agreement Establishes Global Exclusivity Across MIRA’s Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / June 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of an Ame…
You can read the full content here

Frequently Asked Questions

What rights did MIRA Pharmaceuticals secure?

MIRA Pharmaceuticals secured worldwide exclusive rights to MIRA-55 and SKNY-1.

What is the focus of MIRA Pharmaceuticals?

MIRA Pharmaceuticals focuses on developing therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders.

How does this agreement benefit MIRA?

The agreement enhances MIRA's strategic flexibility for future licensing and partnership opportunities.

When was the announcement made?

The announcement was made on June 4, 2026.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA-55 SKNY-1 therapeutics clinical-stage
Last updated: Jun 4, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →